The startup has developed a brain biomarker technology that utilizes magnetic resonance imaging to measure cortical disarray, providing an index of cellular circuit health in the brain. This technology enables early and differential diagnosis of cognitive diseases, particularly Alzheimer's, allowing for timely intervention and treatment.
Funding
$8.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for diagnosing and monitoring neurodegenerative diseases, such as Alzheimer's, often rely on measuring brain volume, which provides limited insight into the underlying cellular changes. This can lead to delayed or inaccurate diagnoses, hindering timely intervention and effective treatment strategies. Existing imaging technologies often fail to detect subtle microstructural changes in the brain that precede significant volume loss.
Solution
Oxford Brain Diagnostics offers CDM Insights, a software-as-a-device solution that analyzes standard clinical MRI scans to provide detailed, quantitative measures of brain microstructure. Powered by Cortical Disarray Measurement (CDM®) technology, the platform assesses grey matter quality by measuring cortical disarray, an index of cellular circuit health. This non-invasive tool supports clinicians in the early and differential diagnosis of neurodegenerative conditions by providing insights into microstructural composition and macrostructural measures. The cloud-native solution delivers outputs in the form of images and numerical values, presented as percentiles of a normative population distribution, enabling healthcare practitioners to monitor brain changes across various stages of adult life.
Target Audience
The primary target audience includes neurologists, radiologists, and clinical researchers focused on neurodegenerative diseases, as well as pharmaceutical and biotech companies involved in drug development for these conditions.
Features
- Analyzes standard clinical MRI scans (1.5T and 3T) to quantify brain microstructure
- Provides Cortical Disarray Measurement (CDM®), a proprietary measure of grey matter quality
- Delivers outputs as images and numerical values, presented as percentiles of a normative population distribution
- Cloud-native platform accessible to neurologists, radiologists, and trained healthcare practitioners
- Supports early and differential diagnosis of neurodegenerative diseases, including Alzheimer's disease
- Facilitates the tracking of disease progression and prediction of decline
- Non-invasive assessment of brain health based on changes in cellular structure
- Provides macrostructural measures in addition to microstructural insights